Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia

OBJECTIVE: MECT combined with ziprasidone treatment refractory schizophrenia clinical effects and adverse reactions, provide the basis for clinical treatment of refractory schizophrenia. METHODS: treated 162 patients with refractory schizophrenia were randomly divided into two groups, the treatment group were treated with MECT combined with ziprasidone treatment, the control group with clozapine plus ziprasidone treatment. respectively before and after treatment 1,2,4 and 8 weeks using the brief psychiatric Rating scale (BPRS) and TESS (TESS) to assess the clinical efficacy and adverse reactions, and compare the clinical efficacy results in 2, 4 and 8 compare four time points, treatment group BPRS scores were significantly lower than the control group, the difference was statistically significant (P <0.05), the total clinical efficiency comparison, the total effective rate was 82.7%, 70.4% in the control group, the difference was statistically significant (P <0.05); the adverse reactions, the treatment group 2 and 4 weeks TESS scores compared with control group showed no significant difference (P> 0.05), but the treatment group 8 weeks TESS scores were significantly lower than the control group, the difference was statistically significant (P <0.05). CONCLUSION: MECT combined with ziprasidone treatment of refractory schizophrenia clinical effect significantly superior to clozapine plus ziprasidone treatment and poor reactions, has a broad clinical application.